| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Applied DNA Sciences (NASDAQ:APDN) reported its Q1 earnings results on Thursday, February 8, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
Applied DNA Sciences beat estimated earnings by 70.97%, reporting an EPS of $-0.09 versus an estimate of $-0.31.
Revenue was down $4.37 million from the same period last year.
Last quarter the company beat on EPS by $0.01 which was followed by a 18.43% drop in the share price the next day.
Here's a look at Applied DNA Sciences's past performance:
| Quarter | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|
| EPS Estimate | -0.27 | -0.24 | -0.2 | -0.29 |
| EPS Actual | -0.26 | -0.24 | -0.2 | -0.30 |
| Revenue Estimate | 1.60M | 2.56M | 4.12M | 4.17M |
| Revenue Actual | 779K | 2.92M | 4.41M | 5.26M |
To track all earnings releases for Applied DNA Sciences visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: APDN
